Abstract
The present review summarizes the available information on the effects of the three major classes of antianginal agents (nitrates, calcium and beta-blockers) on myocardial energy metabolism. It also discusses the role of some new molecules (L-carnitine trimetazidine and ranolazine) that have been proposed as an alternative pharmacological approach for the metabolic management of cardiac ischaemic syndromes.
Original language | English |
---|---|
Pages (from-to) | 2-5 |
Number of pages | 4 |
Journal | European Heart Journal |
Volume | 14 |
Issue number | SUPPL. G |
Publication status | Published - 1993 |
Keywords
- Antianginal drugs
- Cardiac metabolism
- Ischaemic heart disease
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine